Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1490)	3/4/1999 9:17:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Drug Makers Talk of Collaboration on Gene Research, WSJ Says Bloomberg News March 4, 1999, 8:24 a.m. ET New York, March 4 (Bloomberg) -- Some 12 and 15 unnamed drug companies are discussing a joint venture whose goal would be to create a genetic map that identifies variations in human DNA that predispose people to illness, the Wall Street Journal reported, citing unnamed people familiar with the talks. While the unnamed drugmakers hold discussions, major drugmakers including Merck & Co., Glaxo Wellcome Plc, SmithKline Beecham Plc, Pfizer Inc., and Bristol-Myers Squibb Co., are working individually to build the genetic maps, and the U.K.'s Wellcome Trust is involved in the partnership negotiations, spurred by concerns that biotech companies will patent their genome research and monopolize the information. Genset SA, the biggest French genetic-research company which has said it plans to patent two genes that predispose men to prostate cancer, won't be affected by the negotiations, Chief Executive Pascal Brandys told the paper. Monsanto Co., the world's No. 2 maker of crop-protection chemicals, is in preliminary talks to merge with DuPont Co., people familiar with the talks told Bloomberg yesterday. (WSJ 3/4 A1 wsj.com) --Tara Beecham in the Princeton newsroom (609) 279-4104 /jjs news.com